Latest news with #Flu
Hamilton Spectator
2 hours ago
- Business
- Hamilton Spectator
Microbix Exhibiting & Presenting at ADLM
MISSISSAUGA, Ontario, July 24, 2025 (GLOBE NEWSWIRE) — Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it will be attending, exhibiting, and presenting at the Association for Diagnostic & Laboratory Medicine ('ADLM') conference taking place in Chicago, Illinois July 28 to 31, 2025. At ADLM, Microbix will exhibit alongside leading firms that provide tests to diagnose and direct treatment of many infectious and other diseases. Microbix will thereby showcase its ever-growing portfolio of quality assessment products ('QAPs™') that help ensure the accuracy of antigen and molecular (i.e., 'PCR' or 'NAAT') tests and their workflows. Microbix will also be meeting with many current and prospective clients to determine how best to support their quality management system needs. Also at ADLM, Microbix will present results of a pilot External Quality Assessment (EQA) program enabled by Microbix QAPs. Its poster is titled 'Quality Control Rapid Response in Pre-Pandemic Preparedness Showcasing a Synthetic H5N1 Genetic Template.' which reviews the performance of novel QAPs for answering the critical question of whether pre-existing molecular tests for Influenza A can accurately detect the emerging H5N1 (Bird Flu) pandemic strain. A Microbix customer and collaborator, American Proficiency Institute ('API'), is presenting a related poster titled 'Evaluation of NAAT Recovery of Highly Pathogenic Avian Influenza A (H5N1) Clade 2.3.4.4b from Novel Proficiency Samples.' After each poster is presented at ADLM, they will be made available at . The two posters detail the results of work first announced on January 13, 2025, whereby Microbix and API disclosed the creation of QAPs and a pilot proficiency testing program for evaluating the performance of Flu tests in detecting H5N1. As widely reported in the media, H5N1 Flu is a novel variant for which the human population does not have established immunity. Accordingly, H5N1 Flu has pandemic potential, with it having thus far caused severe disease or death in approximately 50% of those persons infected. Microbix gratefully acknowledges the vital role of API in helping to conduct this societally important work. Amer Alagic, Microbix's Director of R&D and lead author of its poster commented, 'Working alongside API, our team is privileged to help answer vital questions concerning the accuracy and usefulness of currently available Flu tests for detecting H5N1. Microbix's novel H5N1 QAPs were created by our team to ensure full genetic coverage of a potential pandemic strain and were made safely under Microbix IP and with cutting-edge synthetic biology techniques. H5N1 QAPs are fully-characterized, accurately-quantified, and are available in liquid and FLOQSwab formats to support both lab-based and point-of-care assays. These Microbix capabilities can be rapidly deployed in response to any emerging pandemic.' Purchase enquiries for these or other Microbix QAPs can be e-mailed to . About Microbix Biosystems Inc. Microbix Biosystems Inc. creates proprietary biological products for human health, with over 120 skilled employees and revenues targeting C$ 2.0 million or more per month. It enables the worldwide commercialization of diagnostic assays by making a wide range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™) that support clinical lab proficiency-testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its antigens drive the antibody tests of approximately 100 diagnostics makers, while QAPs are sold to clinical lab accreditation organizations, diagnostics companies, and clinical labs. Microbix QAPs are now available in over 30 countries, supported by a network of international distributors. Microbix is ISO 9001 & 13485 accredited, U.S. FDA registered, Australian TGA registered, Health Canada establishment licensed, and provides IVDR-compliant CE marked products. Microbix also applies its biological expertise and infrastructure to develop other proprietary products and technologies, most notably Kinlytic® urokinase, a biologic thrombolytic drug used to treat blood clots, and reagents or media to support molecular diagnostic testing (e.g., its DxTM™ for patient-sample collection). Microbix is traded on the TSX and OTCQX, and headquartered in Mississauga, Ontario, Canada. Forward-Looking Information This news release includes 'forward-looking information,' as such term is defined in applicable securities laws. Forward-looking information includes, without limitation, discussion of API, the pilot proficiency testing program, the H5N1 QAPs, or their relevance, Microbix's or others' products or services, business and business results, goals or outlook, risks associated with financial results and stability, development projects such as those referenced in its presentations, regulatory compliance and approvals, access and sales to foreign jurisdictions, engineering and construction, production (including control over costs, quality, quantity or timeliness of delivery), currency exchange rates, maintaining adequate working capital or raising new capital on acceptable terms or at all, and other similar statements about anticipated future events, conditions or results that are not historical facts. These statements reflect management's current estimates, beliefs, intentions, and expectations; they are not guarantees of future performance. Microbix cautions that all forward-looking information is inherently uncertain and actual performance may be affected by many material factors, some of which are beyond its control. Accordingly, actual future events, conditions and results may differ materially from the estimates, beliefs, intentions, and expectations expressed or implied in the forward-looking information. All statements are made as of the date of this news release and represent Microbix's judgement as of the date of this new release, and it is under no obligation to update or alter any forward-looking information. Please visit or for recent Microbix news and filings. For further information, please contact Microbix at: Copyright © 2025 Microbix Biosystems Inc. Microbix®, DxTM™, Kinlytic®, and QAPs™ are trademarks of Microbix Biosystems Inc. FLOQ® and FLOQSwab® are trademarks of Copan Italia S.p.A. Other companies' names and products are protected by their respective trademarks.
Yomiuri Shimbun
18-06-2025
- Health
- Yomiuri Shimbun
Japan Suspends Imports of Fertile Eggs, Day-Old Chicks from Two Brazilian States
Reuters Test tubes are seen labelled 'Bird Flu' words in this illustration taken, June 10, 2024. SAO PAULO, June 17 (Reuters) – Japan suspended imports of fertile eggs and day-old chicks coming from the Brazilian states of Goias and Mato Grosso after bird flu cases in subsistence farms had been reported in both states, the Brazilian Agriculture Ministry said on Tuesday. In a statement, the ministry added that Japan also suspended all poultry meat imports from the cities where the cases were reported, Santo Antonio da Barra in Goias and Campinapolis in Mato Grosso.
Yahoo
06-06-2025
- General
- Yahoo
Fighting against the spread of Measles
Rapid City, S.D. (KELO) — An increased number of measles cases is spreading across the country, with one case being reported in Meade County earlier this week. Public safety alert issued for 'dangerous subject' at large The current cases of Measles started from people who have come back to the country from international travels where measles is endemic. 'The virus is taking hold in communities where vaccination rates are low and that's the really tough thing, measles is incredibly contagious. Experts estimate that we need to have a 95% vaccination rate or better in order to prevent outbreaks from taking hold,' Monument Health Pediatrician Dr. Paula Marsland said. These percentages have dropped to around 90% across the country. Medical professionals are recommending the MMR vaccine (Measles-Mumps-Rubella Vaccination), something that has remained the same for the past 50 years. 'It's not hanging out in animals, it's hanging out in humans. And so as we try to eradicate it, the only way to do that is to stop the transmission of human to human. That's why I mentioned previously, it's highly contagious. Measles is three times more contagious than the Flu, than Covid, than Ebola,' Dr. Marsland said. The last time this many cases happened in the country was back in 2019, when over 1,200 cases were reported for the entire year. 'And then once symptoms show up, folks are infectious from roughly four or five days before the rash starts to four days after the rash starts. So that's a good eight to nine-day period where they are infectious. So certainly if you had somebody with a positive measles case, we'd want them to quarantine until at least four days after the rash started,' Dr. Marsland said. Currently, there have been over 1,100 cases this year, with over two-thirds being in people ages 19 and younger. The measles vaccine is typically given between 12-15 months of age with the second dose of MMR given in the range of 4-6 years of age. If you want to learn more about next steps in preventing measles, talk to your medical professional or find more informaiton here. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
30-05-2025
- Business
- Yahoo
📹 Fluminense cruise past Once Caldas, reach Sudamericana last 16
Fluminense did what was expected of them on Thursday night (29) in front of 33,688 fans. And advanced directly to the round of 16 of the Copa Sudamericana, earning $600,000 (R$ 3.4 million) in prize money. Advertisement Thanks to goals from Martinelli and Serna, they beat Once Caldas 2-0 at the Maracanã. Taking the lead from the Colombian team in Group F. Which eliminated two matches in the already tight schedule against a Libertadores team. Check out the best moments of the match below (Available only in Brazil) Tricolor advantage The clock had not yet reached two minutes when Martinelli, with his left foot, opened the scoring. Fluminense controlled the actions, dictated the pace of the game. Almost celebrated a penalty in Serna, but the VAR made the referee change his mind. Once Caldas only posed a real threat once before halftime, with Mateo García. Advertisement It was up to the insistent Serna to beat Aguirre high to increase the tricolor advantage (34'). Once Caldas tries and Flu controls The Colombian team needed a comeback to return to being the leader. And had moments when they had more possession and volume of play. But without creating real scoring chances. Renato made the imagined changes. Flu did not show the same lethality seen before halftime, but was safe without the ball. And celebrated the spot in the round of 16 in their farewell to the fans before the World Cup. 📊 Situation in the key and schedule 📅 Fluminense reached 13 points, leaving Once Caldas with 12. Advertisement It was the only Brazilian team to advance directly to the round of 16 of the Sudamericana. And had the fourth-best campaign in the group stage. Will find out on the second (2) which crossover of the playoffs will yield their rival in that phase. Returns to focus on the Brasileirão. Will travel to Porto Alegre to face Internacional on Sunday (1st). Game for the 11th round of the competition. Their last commitment before thinking exclusively about the Super World Cup. This article was translated into English by Artificial Intelligence. You can read the original version in 🇧🇷 here. 📸 PABLO PORCIUNCULA - AFP or licensors
The Hindu
28-05-2025
- Health
- The Hindu
Haryana Health Department issues advisory to combat rising COVID-19 cases; 24 cases reported this month
Amid the rise in COVID-19 cases in Haryana, the State Health Department issued a 10-point advisory reiterating the need to remain vigilant, and ensure effective preparedness. Six fresh cases were reported on Wednesday, taking the total number of patients in the State to 24 this month so far. A total of 78 samples were taken on Wednesday. The number of active cases is 14, and no death has been reported so far. Chief Minister Nayab Singh Saini, after a meeting with the senior Health officials in Chandigarh, said there was no need to panic and the State was prepared to deal with any situation. The advisory, issued by Director General (Health) Manish Bansal, to the Civil Surgeons, directs them to set up Flu corners and ensure health preparedness in terms of availability of beds, isolation beds, oxygen, antibiotics and other drugs. It emphasises the need to sensitise and re-orient health staff by providing refresher training on COVID-19 signs, symptoms, management and guidelines. It also directs the district health officials to ensure availability of N-95 mask and Reagent kits. The DG directs the Civil Surgeons to monitor the patients in home isolation, especially the high-risk cases involving the elderly, pregnant women, children and those with comorbidities. It also stresses the need to create awareness regarding appropriate COVID-19 behaviour like adherence to respiratory and hand hygiene. 'District Surveillance Unit shall closely follow the trend of influenza-like illness (ILI) and severe acute respiratory infections (SARI) in the area, monitor the proportion of SARI cases among all ILI and SARI cases, and refer sufficient number of samples for testing as per revised surveillance strategy,' reads the advisory. It also seeks timely updating of the data and holding of meetings with the Indian Medical Association members for preparedness. Gurugram has reported the highest number of 11 cases in the State, followed by Faridabad (9), Karnal (3) and Yamunanagar (1).
